The mechanisms tumor cells utilize to evade the host's immune system

被引：49
作者：
Kuol, Nyanbol [1 ]
Stojanovska, Lily [1 ]
Nurgali, Kulmira [1 ]
Apostolopoulos, Vasso [1 ]
机构：
[1] Victoria Univ, Coll Hlth & Biomed, Ctr Chron Dis, POB 14426, Melbourne, Vic 8001, Australia
来源：
MATURITAS | 2017年 / 105卷
关键词：
Programmed death-ligand 1; Indoleamine-2,3-dioxygenase; Siglec-9; Major histocompatibility complex; Tumor escape; MHC CLASS-I; BREAST-CANCER CELLS; REGULATORY T-CELLS; PD-L1; EXPRESSION; SUPPRESSOR-CELLS; POOR-PROGNOSIS; INFILTRATING LYMPHOCYTES; COLORECTAL-CANCER; DOWN-REGULATION; GROWTH-FACTOR;
D O I：
10.1016/j.maturitas.2017.04.014
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
The immune system plays an essential role in the tumor progression; not only can it inhibit tumor growth but it can also promote tumor growth by establishing a favorable environment. Tumor cells utilize several strategies to evade the hoses immune system, including expression of immunosuppressive molecules such as PD-L1, IDO and siglec-9. In addition, tumor cells not only regulate the recruitment and development of immunosuppressive forces to influence the tumor microenvironment but also shift the phenotype and function of normal immune cells from a possibly anti-tumor state to a pro-tumor state. As a result, tumor cells evade the hoses immune system, leading to metastasis and/or recurrent disease.
引用
收藏
页码：8 / 15
页数：8
相关论文
共 142 条
[1]   PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes [J].
Ali, H. R. ;
Glont, S. -E. ;
Blows, F. M. ;
Provenzano, E. ;
Dawson, S. -J. ;
Liu, B. ;
Hiller, L. ;
Dunn, J. ;
Poole, C. J. ;
Bowden, S. ;
Earl, H. M. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2015, 26 (07) :1488-1493
[2]   Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells [J].
Alsuliman, Abdullah ;
Colak, Dilek ;
Al-Harazi, Olfat ;
Fitwi, Hanaa ;
Tulbah, Asma ;
Al-Tweigeri, Taher ;
Al-Alwan, Monther ;
Ghebeh, Hazem .
MOLECULAR CANCER, 2015, 14
[3]   Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis [J].
Andersson, Emilia ;
Poschke, Isabel ;
Villabona, Lisa ;
Carlson, Joseph W. ;
Lundqvist, Andreas ;
Kiessling, Rolf ;
Seliger, Barbara ;
Masucci, Giuseppe V. .
ONCOIMMUNOLOGY, 2016, 5 (01)
[4]   MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro [J].
Angell, Trevor E. ;
Lechner, Melissa G. ;
Jang, Julie K. ;
LoPresti, Jonathan S. ;
Epstein, Alan L. .
CLINICAL CANCER RESEARCH, 2014, 20 (23) :6034-6044
[5]  
[Anonymous], GUT
[6]   MUC1 (CD227): a multi-tasked molecule [J].
Apostolopoulos, Vasso ;
Stojanovska, Lily ;
Gargosky, Sharron E. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (23) :4475-4500
[7]   B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells [J].
Azuma, Takeshi ;
Yao, Sheng ;
Zhu, Gefeng ;
Flies, Andrew S. ;
Flies, Sarah J. ;
Chen, Lieping .
BLOOD, 2008, 111 (07) :3635-3643
[8]   Prognostic significance of PD-L1 and PD-L2 in breast cancer [J].
Baptista, Mauricio Z. ;
Sarian, Luis Otavio ;
Derchain, Sophie F. M. ;
Pinto, Glauce A. ;
Vassal, Jose .
HUMAN PATHOLOGY, 2016, 47 (01) :78-84
[9]   Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes [J].
Belisle, Jennifer A. ;
Horibata, Sachi ;
Jennifer, Gubbels A. A. ;
Petrie, Sarah ;
Kapur, Arvinder ;
Andre, Sabine ;
Gabius, Hans-Joachim ;
Rancourt, Claudine ;
Connor, Joseph ;
Paulson, James C. ;
Patankar, Manish S. .
MOLECULAR CANCER, 2010, 9
[10]   Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages [J].
Bloch, Orin ;
Crane, Courtney A. ;
Kaur, Rajwant ;
Safaee, Michael ;
Rutkowski, Martin J. ;
Parsa, Andrew T. .
CLINICAL CANCER RESEARCH, 2013, 19 (12) :3165-3175
12345678910